This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Inotuzumab Ozogamicin

Pfizer Inc.

Drug Names(s): PF-5208773, CMC544, CNC-544

Description: CMC-544 is an anti-CD22 antibody conjugated to calicheamicin, a cytoxic drug, using technology developed for Mylotarg.

Deal Structure: Celltech entered into a collaboration with Wyeth in 1991 for the research, development and commercialization of antibody cytotoxic conjugates as novel oncology treatments. Mylotarg arose out of this collaboration. Under the terms of the collaboration, Wyeth is responsible for clinical development and funds the majority of trial costs for CMC-544. Celltech contributes a portion of clinical development costs. Celltech will receive royalties on world-wide sales of any products that are successfully commercialized. In 2004, UCB acquired Celltech.

In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The acquisition was completed in October 2009.

Partners: UCB SA

Inotuzumab Ozogamicin News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug